Summit Therapeutics (SMMT) Net Cash Flow Growth (5y) (2024 - 2026)
Summit Therapeutics (SMMT) Net Cash Flow Growth (5y) (2024 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,908.96 Bn | 1,908.90 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 474.03 Bn | 469.24 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.09 Bn | 61.34 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.53 Bn | 34.52 Bn | 959.66 Mn |
| 10 | Summit Therapeutics | 10.49 Bn | 9.80 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 233.62% |
| Mar 31, 2026 | -39.98% |
| Dec 31, 2025 | -18.25% |
| Sep 30, 2025 | -28.87% |
| Jun 30, 2025 | 45.95% |
| Mar 31, 2025 | 69.66% |
| Dec 31, 2024 | -18.31% |
| Mar 31, 2024 | -21.85% |